RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $200,000 | +85.2% | 26,165 | +80.6% | 0.00% | – |
| Q2 2023 | $108,000 | +103.8% | 14,489 | +83.2% | 0.00% | – |
| Q1 2023 | $53,000 | -69.2% | 7,908 | -64.7% | 0.00% | – |
| Q4 2022 | $172,000 | +719.0% | 22,409 | +1051.0% | 0.00% | – |
| Q3 2022 | $21,000 | +162.5% | 1,947 | +92.4% | 0.00% | – |
| Q2 2022 | $8,000 | -84.3% | 1,012 | -85.7% | 0.00% | – |
| Q1 2022 | $51,000 | -88.0% | 7,081 | -71.5% | 0.00% | – |
| Q4 2021 | $425,000 | +553.8% | 24,803 | +770.6% | 0.00% | – |
| Q3 2021 | $65,000 | +22.6% | 2,849 | +97.2% | 0.00% | – |
| Q2 2021 | $53,000 | – | 1,445 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |